Achieve Life Sciences, Inc. (ACHV)

Latest News

View All News

June 30, 2025 7:52 PM EDT

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities View Press Release

Jun 26, 2025 11:43 pm EDT

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025 4:03 pm EDT

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025 4:02 pm EDT

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

View All News

Latest Presentation

Achieve Corporate Presentation 2025 View Presentation

View All Presentations

Latest Financial Results

Q1 2025

Quarter Ended Mar 31, 2025

Earnings Release

Earnings Webcast

10-Q XBRL Zip

View All Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

View 10-K

Company Overview

Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

View Management Team View Board of Directors

IR Contacts

Headquarters

Achieve Life Sciences, Inc.
22722 29th Dr. SE
Suite 100
Bothell, WA 98021
United States
T: 425-686-1500

Investor Relations

Nicole Jones
T: 425-686-1510
ir@achievelifesciences.com